Order: Aripiprazole 15 mg PO q24hr

Available: Refer to the med label below

How many milliliters will you administer per dose? (Insert the numerical value only)

A. Montelukast: This leukotriene receptor antagonist is used for long-term asthma control and prevention of exercise-induced bronchospasm. It is not effective for treating acute asthma attacks due to its delayed onset of action.
B. Salmeterol: This is a long-acting beta-2 agonist (LABA) used for maintenance therapy in asthma. It has a slower onset and should never be used for rapid symptom relief during an acute attack, as doing so can delay appropriate treatment.
C. Albuterol: Albuterol is a short-acting beta-2 agonist (SABA) that provides rapid bronchodilation and is the first-line rescue medication for aborting an acute asthma attack. It works within minutes to relieve bronchospasm and improve airflow.
D. Beclomethasone: This inhaled corticosteroid is used for long-term asthma management by reducing airway inflammation. It is not effective in acute situations because it does not provide immediate bronchodilation.

A. To decrease the cost of medication for the patient: While cost may be a consideration in long-term therapy, it is not the primary reason for tapering corticosteroids. The tapering process is necessary to protect the patient’s physiological balance, not driven by cost concerns.
B. To prevent the risk of acute adrenal insufficiency: Long-term prednisone use suppresses the hypothalamic-pituitary-adrenal (HPA) axis. Abrupt discontinuation can lead to adrenal insufficiency, a potentially life-threatening condition characterized by hypotension, fatigue, and electrolyte imbalances. Gradual tapering allows the adrenal glands to resume natural cortisol production.
C. To minimize the potential for drug interactions: Tapering does not reduce drug interactions. Such risks are managed through medication reconciliation and monitoring, not by adjusting steroid taper schedules.
D. To reduce the likelihood of rheumatoid arthritis flare-up: While tapering may reduce flare risk, the primary concern is adrenal suppression. Flare prevention is managed with other disease-modifying agents rather than the tapering schedule alone.